Criteria for evaluation of disease extent by 123 I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1319-1326

  Matthay, K K ^a   Shulkin, B ^b   Ladenstein, R ^c   Michon, J ^d   Giammarile, F ^e   Lewington, V ^f   Pearson, A D J ^g   Cohn, S L ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d INSTITUT CURIE   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

International Neuroblastoma Risk Group (INRG); MIBG; Minimal disease; Neuroblastoma; Response criteria

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; COCAINE; DULOXETINE; LABETALOL; NORADRENALIN TRANSPORTER; PENTETREOTIDE IN 111; PHENOTHIAZINE; PHENYLPROPANOLAMINE; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; PSEUDOEPHEDRINE; RADIOPHARMACEUTICAL AGENT; RESERPINE; VENLAFAXINE;

ARTIFACT; BONE METASTASIS; CANCER STAGING; CONSENSUS; DRUG CROSS REACTIVITY; HUMAN; IMAGE QUALITY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 77951688395     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605621     Document Type: Review

References (68)

1. Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, Gongora R, Manil L (1995) A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 31A: 256-261
2. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100: 1471-1482
3. Babich JW, Graham W, Fischman AJ (1997) Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblas-toma cells. Eur J Nucl Med 24: 538-543
4. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Chon SL, Pearson ADJ, Matthay KK (2009) Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group (INRG) Task Force. J Clin Oncol 100(10): 1627-1637
5. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L, Reske SN (2003) 131I/123I- metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30: BP132-BP139
6. Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE (1999) Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Gene Ther 6: 1147-1152
7. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Lampert F, Lee REJ, Look AT, Pearson ADJ, Phillip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment [see comments]. J Clin Oncol 11: 1466-1477
8. Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, Board J, George RE, Ellershaw C, Pearson AD, Lunec J, Montaldo PG, Ponzoni M, van Eck-Smit BL, Hoefnagel CA, van den Brug MD, Tytgat GA, Caron HN (2003) Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 9: 3338-3344
9. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297
10. De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD (2009) Excellent outcome with reduced treatment for infants with disseminated neuro-blastoma without MYCN gene amplification. J Clin Oncol 27: 1034-1040
11. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN (2008) Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 44(4): 551-556
12. DuBois SG, Matthay KK (2008) Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35(Suppl 1): S35-S48
13. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, Wioland M, Gomez F (2000) Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 34: 237-241
14. Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G, Claudiani F, De Bernardi B (1999) 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 81: 1378-1384
15. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST (2005) Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20: 195-199
16. Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ (1994) Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35: 1753-1757
17. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35: 1039-1047
18. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J (1990) Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-MIBG scans [see comments]. J Nucl Med 31: 129-134
19. Guilloteau D, Chalon S, Baulieu JL, Huguet F, Desplanches G, Chambon C, Vilar MP, Pourcelot L, Besnard JC (1988) Comparison of MIBG and monoamines uptake mechanisms: pharmacological animal and blood platelets studies. Eur J Nucl Med 14: 341-344
20. Hadley GP, Rabe E (1986) Scanning with iodine-131 MIBG in children with solid tumors: an initial appraisal. J Nucl Med 27: 620-626
21. Hero B, Hunneman DH, Gahr M, Berthold F (2001) Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 36: 220-223
22. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F (2008) Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 26: 1504-1510
23. Hickeson MP, Charron M, Maris JM, Brophy P, Kang TI, Zhuang H, Khan J, Nevrotski T (2004) Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 42: 268-274
24. ICRP (1998) Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 28: 1-126
25. Jacobs F, Thierens H, Piepsz A, Bacher K, Van de Wiele C, Ham H, Dierckx RA (2005) Optimised tracer-dependent dosage cards to obtain weight-independent effective doses. Eur J Nucl Med Mol Imaging 32: 581-588
26. Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, Schmoldt J, Liu D, Rademaker AW, Kletzel M (2004) Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 22: 3909-3915
27. Kushner BH, Kramer K, Modak S, Cheung NK (2009) Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 27: 1041-1046
28. Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK (2003) Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 21: 1082-1086
29. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19: 3397-3405
30. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16: 953-965
31. Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F (2007) The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 34: 796-798
32. Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, Hartmann O, Hoefnagel CA, Jamadar DA, Kloos R, Lizotte P, Lumbroso J, Rufini V, Shulkin BL, Sisson JC, Thein A, Troncone L (1997) Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38: 1352-1357
33. Lewington V, Bar Sever Z, Lynch T, Giammarile F, McEwan A, Shulkin B, Staudenherz A, Ladenstein R (2009) Development of a new, semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma. Eur J Nucl Med Mol Imaging 36: 334
34. Lindauer A, Siepmann T, Oertel R, Jung A, Ziemssen T, Jaehde U, Kirch W, Siepmann M (2008) Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. Clin Pharmacokinet 47: 721-731
35. Lumbroso JD, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Leclere JG, Couanet D, Bayle C, Caillaud JM, Lemerle J et al (1988) Meta- iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 271: 689-705
36. Mairs RJ, Livingstone A, Gaze MN, Wheldon TE, Barrett A (1994) Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer 70: 97-101
37. Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J (2003a) Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 98: 155-165
38. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J (2003b) Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21: 2486-2491
39. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM (2009) Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 27: 1020-1025
40. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myelo-ablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24: 500-506
41. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblasto-ma. J Clin Oncol 25: 1054-1060
42. McCluskey AG, Boyd M, Ross SC, Cosimo E, Clark AM, Angerson WJ, Gaze MN, Mairs RJ (2005) [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 11: 7929-7937
43. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, Maris JM, Yanik G, Hawkins RA, Matthay KK (2006) Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 47: 865-874
44. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27: 298-303
45. Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, Burnazi E, Finn RD, Doubrovin M, Blasberg RG (2007) Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med 48: 827-836
46. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18: 477-486
47. Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F, Gordon I, Hahn K, Kabasakal L, Mann M, Mitjavila M, Piepsz A, Porn U, Sixt R, van Velzen J (2003) Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 30: B45-B50
48. Parisi MT, Matthay KK, Huberty JP, Hattner RS (1992) Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology 184: 463-467
49. Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A, Cohn SL (1999) Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 21: 13-18
50. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 18: 18-26
51. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, Schmid I, Hahn K (2003) Integrated imaging using MRI and 123I metaiodoben-zylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 181: 1115-1124
52. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, Klein M (2008) Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromo-cytoma. AJR Am J Roentgenol 190: 1085-1090
53. Rubie H, Michon J, Plantaz D, Peyroulet MC, Coze C, Frappaz D, Chastagner P, Baranzelli MC, Maechinaud F, Boutard P, Lutz P, Perel Y, Leverger G, de Lumley L, Millot F, Staephan JL, Margueritte G, Hartmann O (1998) Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Sociaetae Franecaise d'Oncologie Paediatrique SFOP. Br J Cancer 77: 2310-2317
54. Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B (1996) Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 37: 1464-1468
55. Rufini V, Giordano A, Di Giuda D, Petrone A, Deb G, De Sio L, Donfrancesco A, Troncone L (1995) [123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 39: 25-28
56. Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgstrom P, Schwarz K, Ambros IM, Treuner J, Kogner P (2000) Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblas-toma provides prognostic information. Med Pediatr Oncol 35: 688-691
57. Schmidt M, Simon T, Hero B, Schicha H, Berthold F (2008) The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma 41 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 44: 1552-1558
58. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK (2000) Biologic factors determine prognosis in infants with stage IV neuroblastoma: a Prospective Children's Cancer Group Study. J Clin Oncol 18: 1260-1268
59. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009) 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 50: 1237-1243
60. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC (1996) Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro- 2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199: 743-750
61. Shulkin BL, Shapiro B (1998) Current concepts on the diagnostic use of MIBG in children. J Nucl Med 39: 679-688
62. Stabin MG, Gelfand MJ (1998) Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 42: 93-112
63. Suc A, Lumbroso J, Rubie H, Hattchouel JM, Boneu A, Rodary C, Robert A, Hartmann O (1996) Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 77: 805-811
64. Taggart D, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Aparici CM, Darlson D, Maris J, Hawkins R, Matthay KK (2009) Comparison of 123I-metaiodobenzylguanidine (MIBG) scan and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate response after 131I-MIBG therapy for neuroblastoma. J Clin Oncol 27(32): 5343-5349
65. Tang HR, Da Silva AJ, Matthay KK, Price DC, Huberty JP, Hawkins RA, Hasegawa BH (2001) Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med 42: 237-247
66. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, Colucci R, Corona T, Blandizzi C, Del Tacca M (2009) Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 31(Part 1): 1426-1453
67. Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, Heiba S, Serafini A, Tumeh S, Khutoryansky N, Jacobson AF (2009) (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer 52: 784-790
68. Yanik GA, Parisi MT, Naranjo A, Matthay KK, London WB, Mcgrady PW, Kreissman SG, Shulkin BL (2010) MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma. a COG study. J Clin Oncol 2010. Supplement ASCO Proceedings, in press